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Abstract For the first time the complete cDNA encoding two 
isoallergens of the non-pyroglyphid dust mite Lepidoglyphus 
destructor, Lep d 1, allergen has been sequenced. In addition, one 
of the isoallergens was found to have two variants. Oligonucleo- 
tides were designed from known amino acid sequences. The 
cDNA sequences were obtained by hybridizing these primers to 
mRNA and enhancement by the RT-PCR technique. To obtain 
the different complete encoding cDNA sequences and eliminate 
heteroduplex artifacts, we performed PCR + 1 reactions. Com- 
parison of the amino acid sequence of the allergen shows leader 
sequences of 16 amino acids for both isoforms. 
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1. Introduction 
Lepidoglyphus destructor (L. destructor) is an important non- 
pyroglyphid mite species in Europe [1-3]. It is the predominant 
allergen in farming environments [3-5]. Allergy to non-pyro- 
glyphid mites has been mostly associated with occupational 
exposure [2-6], but people living in damp housing conditions 
may also be exposed [7]. Until recently, the characterization of
mite allergens has focused on the house dust mite Dermato- 
phagoides pecies. The major allergens of these species have been 
studied in detail with physicochemical nd recombinant tech- 
nology. However, only a few studies have been performed on 
storage mite L. destructor allergens [8-11]. 
We have identified at least twenty IgE-binding components 
in the molecular weight range of 13-93 kDa [8,9]. The major 
allergen of L. destructor, Lep d 1, is a protein of approximately 
15,000 dalton and is recognized by about 90% of sera RAST 
positive to this mite species. Lep d 1 has been purified and its 
amino acid sequence has been reported [10,11]. Polymorphism 
for this protein has been discussed based on peptide analysis; 
however, Varela et al. [11] did not distinguish different isoaller- 
gens and their variants, since their data were based on protease- 
digested protein fragments. This is the first report of the com- 
plete encoding cDNA sequence of two isoallergens and its 
variants of the Lep d 1 major allergen. 
2. Material and methods 
2.1. Isolation of mRNA 
L. destructor cultures were obtained from Allergon AB (,~ngelholm, 
Sweden). The isolation of mRNA was carried out using the PolyAT- 
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tract System 1000 (Promega, Scandinavian Diagnostic Services, 
Falkenberg, Sweden). Briefly, approximately 0.5 g of mite culture was 
homogenized in 4 ml extraction buffer containing 2% fl-mercaptoethanol. 
After addition of 8 ml of preheated ilution buffer and 500 pmol of 
biotinylated oligo(dT), the sample was incubated at 70°C for 5 min. The 
solution was centrifuged at 12,000 x g for 10 min at room temperature. 
The supernatant was transferred and incubated with 6 ml of Strep- 
tavidin MagneSphere Paramagnetic Particles at room temperature for 
2 min. After washing three times with 0.5x SSC and capturing the 
magnetic particles with a magnetic stand, the mRNA was eluted with 
3 ml water. The nucleic acid was then alcohol precipitated. 
2.2. Construction foligonucleotide primers for PCR 
Two degenerate oligonucleotides (primer 1 and primer 2) were de- 
signed according to the known amino acids [10,11]. Primer 1 was in 
sense orientation and corresponded with the N-terminal end, primer 2 
was in anti-sense direction according to amino acids 37 to 42. In addi- 
tion, for the 3' RACE protocol match primer 3 and oligo(dTl and dT2) 
were used; for the 5' RACE protocol match primers 4, 5 and a 5' anchor 
primer (Gibco/BRL, Life Technologies, T~iby, Sweden) were utilized. 
Sense primers (6, 7) were designed for the PCR + 1 reactions; primer 
7 shows the same sequence as primer 6 but has an additional restriction 
endonuclease (RE) site, HindIII, at the 5' end. All primers are listed in 
Table 1. 
2.3. PCR amplification 
Reverse transcriptase polymerase chain reaction (RT-PCR) was used 
to amplify the RNA and to obtain three overlapping cDNA fragments 
using the following primer combinations: primer 1 and primer 2; primer 
3, oligo(dT1) and oligo(dT2); primer 4 and primer 5 with 5' RACE 
anchor primer. 
The amplification of the middle fragment of Lep d 1 allergen cDNA 
was based on standard protocols. Briefly, poly(A)-selected RNA was 
added to 1/.tmol of oligonucleotide primer 2 in a 10/A volume, heated 
to 70°C for 10 min and then chilled on ice. The following solutions were 
added to the final concentration i I x first strand synthesis buffer 
(BRL): 0.5 mM each dNTP and 10 mM dithiothreitol. After 2 min at 
42°C, 200 units of Superscript RNAse H- (BRL) were added and the 
reaction incubated for 30 min at 42°C. The mixture was then heated 
to 55°C for 5 min, 2 units of RNAse H added, and incubated for 10 
min at 55°C, then chilled on ice. The cDNA was purified using glass- 
max columns (BRL). The PCR amplification was carried out using 
primer 1 and primer 2 (each 0.4/,tM) in 1 x extender buffer (Stratagene, 
AH Diagnostics AB, Sk~irholmen, Sweden) containing 0.25 mM each 
dNTP and overlaid with 1 volume of mineral oil. After an initial denatu- 
ration at 94°C for 8 min, 5 units ofTaq polymerase (BRL) and an equal 
amount of Taq extender (Stratagene) were added at 80°C. The mixture 
was then subjected to 40 cycles of amplification in an MJ Research 
Minicycler: 1 min at 94°C, 2 min at 55°C, and 2.5 min at 72°C. 
The 3' fragments were PCR amplified using the same conditions as 
described above with the primers oligo(dT1) for cDNA synthesis, and 
the primers oligo(dT2) and 3 for the PCR reactions. The 5' fragments 
were obtained using primer 4 for the cDNA synthesis, then the frag- 
ments were tailed with 1 mM dCTP and 30 units terminal dideoxytrans- 
ferase according to manufacturer's protocol (BRL). PCR amplifica- 
tions were performed as described above using primer 5 and 5' anchor 
primer (BRL). 
2.4. PCR + 1 reactions 
Synthesis of cDNA from mRNA was performed exactly under the 
same conditions as described above for the 3' PCR fragments. The first 
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part ofPCR + 1 [12] reactions were carried out in 50/al containing one 
half (20/al) of the cDNA sample, 0.25 mM of each NTP, 50/aM primer 
oligo(dT2), 5/aM primer 6 (a sense primer starting 10 nucleotides 
upstream from the initial codon and ending with nucleotide 11 of the 
leader sequence) in 1 x extender buffer. Taq polymerase and extender 
were added under hot start conditions as described above. Additionally, 
we added 1/al of Perfect match (Stratagene) to increase the specificity 
of primer annealing. Each of the 30 amplification cycles consisted of: 
94°C for 2 min, 50°C for 2 min, 72°C for 3 min. The final extension 
was for 10 min at 72°C. 
The second part of PCR + 1 reactions contained 25/al of the first 
reaction sample from above and 50/aM of primer 7. Additionally, Taq 
polymerase and extender were added under hot start conditions, and 
a single cycle was performed as described above. The reactions were 
then cooled to 4°C. 
2.5. Cloning and screening of PCR and PCR + 1 reactions 
All amplified products were analyzed by electrophoresis, and the 
positive samples were eluted from the agarose gels. Isolated DNA's 
from PCR reactions were directly cloned into TA3 plasmid using the 
TA cloning kit (Invitrogen). After transformation, plasmid DNA mini- 
preparations from bacterial colonies were digested with the appropriate 
RE(s). Namely, EcoRl for PCR fragments and HindIII for the PCR + 1 
fragments. The potential PCR + 1 clones were analyzed by gel electro- 
phoresis according to the expected size. The identification fcomplete 
PCR + 1 clones was confirmed by DNA sequencing of the incorporated 
primer 7, which contains aHindIII site at the 5' end, into the PCR + 1 
fragments. 
2.6. DNA sequencing 
Recombinant plasmids were sequenced bythe dideoxy chain termi- 
nation method using the Sequenase 2.0 kit (US Biochemical, Amersham 
Sweden AB, Solna, Sweden) and SP6 and T7 promotor sequencing 
primers. 
3. Results and discussion 
In order to obtain the complete cDNA sequence of Lep d 1 
major allergen, we utilized RT-PCR, PCR + 1 and standard 
cloning techniques. We first amplified a small fragment using 
degenerated primers 1 and 2, which were designed according 
to the known amino acid sequence. The 3' fragments were 
obtained with both oligo(dT) primers and match primer 3. The 
amplification of the 5' fragments were performed using primer 
4 for cDNA synthesis followed by the nested primer 5 in com- 
bination with the anchor primer (BRL). Three independent 
PCR reactions were performed for the 3' RACE and 5' RACE. 
The cloned PCR fragments were sequenced and analyzed 
using the DNASIS (National Biosciences) and Genetic Com- 
puter Group (Wisconsin) software packages. The data obtained 
from a minimum of three independent clones of the 3' and 5' 
fragments indicated that we had amplified at least wo isoaller- 
gens. The nucleotide composition differed at some positions in 
both the coding and the non-coding regions. 
The formation of heteroduplex DNA arising from quasi- 
Table 1 
List of primers used in PCR and PCR + 1 
homologous sequences u ing PCR has been described [13]. Bor- 
riello and Krauter [12] have reported the complications arising 
from artifactual DNA sequences via mismatch repair during 
amplification and subcloning into bacteria which will repair the 
mismatches randomly for replication. This generates sequences 
from which it is difficult to determine the real sequences. To 
overcome these artifacts, they developed the PCR + 1 method- 
ology and this PCR technique has been, meanwhile, success- 
fully applied when polymorphism is present [14,15]. We have 
designed the primers for the 5' end of the PCR + 1 method to 
a conserved region we have found after sequencing 9 clones of 
two independent 5' RACE PCR reactions. This area stretches 
from 10 nucleotides before the initial codon into the third 
amino acid of the leader sequence. For the 3' end, we have used 
the oligo(dT1 and dT2) primers. This enabled us to survey a 
broader ange of possible variants of this protein. In order to 
increase the specificity of the products, we have added Perfect 
Match (Stratagene) to the reactions. 
Sequencing ofpotential PCR + 1 clones confirmed that 97% 
of the screened clones contained the restriction site HindIII at 
the 5' end. We have minutely examined 28 PCR + 1 clones of 
6 independent reactions and identified two isoallergens, one 
with two variants. The identification was based on sequences 
that were identical from clones of at least two independent 
reactions. We have named these allergens according to the new 
allergen omenclature [16] Lep d 1.0101, Lep d 1.0102 and Lep 
d 1.02. Only 6 out of 28 (21.4%) clones represented Lep d 1.02, 
whereas the two variants Lep d 1.0101 and Lep d 1.0102 were 
equally represented (each 39.3%). The data for all three forms 
further show a common leader sequence corresponding to 16 
amino acids which has hitherto never been reported. In Fig. 1 
we show the nucleotide sequences of these forms of Lep d 1. 
The two variants Lep d 1.0101 and Lep d 1.0102 show differ- 
ences of 6 nucleotides in the encoding part of the cDNA which 
are silent mutations. The non-coding 3' end indicates a block 
mutation and lengthens the cDNA of the latter by one nucleo- 
tide (Fig. 1). Lep d 1.0102 is identical in the coding area with 
clone L2 described by Varela et al. [11]; however, the non- 
coding 3' end reveals differences between the polyA signal and 
the polyA tail and additionally 15-5 nucleotides upstream of 
the polyA signal (Fig. 3). These differences may be due to a 
slight variability in the site of the oligo(dT) primer annealing 
and/or to the presence of further variants in the mite popula- 
tion. 
The mutations in Lep d 1.02 are more numerous (Fig. 1) and 
lead to 13 changes (10.4%) of the amino acid composition of 
the protein (Fig. 2). Earlier, Varela et al. [11] have postulated 
the possible polymorphism of Lep d 1. Their arguments were 
based on the amino acid sequence of overlapping peptides and 
primer 1 
primer 2 
primer 3 
primer 4 
primer 5 
oligo(dT1) 
oligo(dT2) 
anchor primer (BRL) 
primer 6 
primer 7 
5'-AA (A/G) ATGACNTT (T/C) AA  (A/G) GA-3' 
5'-GCNGC (A/G) AA ( T/C ) TTNGC (T/C) T-3' 
5'-GAACTTGACATCACGGGCTGC-3' 
5 ' -CCGCAAGCCATGACAC CGTGGTCTCCGATC-3'  
5'-AATTTGGCC TC CAAAGTCATCTTCT-3'  
5'-TCTGAATTC TCGAGTCGACATC TTTTTTTTTTTTTTTTT-  3' 
5 '-TCTGAATTC TCGAGTCGACATC T-3' 
5 ' -CUACUACUACUAGGC CACGCGTCGACTAGTACGGG I IGGGI IGGGI IG- 3 ' 
5 ' -ACAATTCAAAATGATGAAATT-3' 
5 ' -GAGAAGCTTACAATTCAAAATGATGAAATT-3'  
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Lep d 1.0101 
Lep d 1.0102 
Lep d 1.02 
Lep d 1.0101 
Lep d 1.0102 
Lep d 1.02 
1 60  
_~_TGATGIM~T ~ T C T  ~q~CCCTT G'I'GGC CG'PI'G CCT~_~__  CAAGATGACC 
61  120  
TTCAAGGACT GCf~FECJECGG AG~GGTTACC ~TTGACA TCACGGGCTG CTCTGGTGAC 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . .  T . . . . . . . .  C . . . . . . . .  C . . . .  - -T  . . . . . . . . . . . . . . . . .  
121 180 
Lep d 1.0101 ACCTGTC-'I'CA TTCACCGI~G AG£C.,,A,I~ATG ACTTTC-G, AAG CCaAATTCGC CC_,-CTAACCAG 
Lep d 1.0102 . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . . . . .  A . . . . . . . . . . .  T . . . . .  C . . . . . .  
Lep d 1 .02  . . . . . . . . . . . . . . . . . . . . .  c . . . . . . . . . . . . . . . .  T . . . . . . . . . . . . . .  C . . . . . .  
Lep d 1.0101 
Lep d 1.0102 
Lep d 1.02 
kep d 1.0101 
kep d 1.0102 
Lep d 1.02 
Lep d 1.0101 
Lep d 1.0102 
Lep d 1.02 
181 240  
Ga~3ACCGCCA AGGTTACCIT  ~'~'L" , " . L 'G  GCCaaC.GTTG CCGGTa%E CAC CATCCAGGTT 
Lep d 1.0101 
Lep d 1.0102 
Lep d 1.02 
Lep d 1.0101 
Lep d 1.0102 
Lep d 1.02 
Lep d 1.0101 
Lep d 1.0102 
Lep d 1.02 
- -T  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . .  AA  . . . . . .  C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  T . . . . . .  
241  300 
CCCGGTTTGG AKACCGgLCGG TTGCAIM~TC ATCI IC+TC~C C A ~  ~ T  
. . . . .  C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . . . . . . . . . . . .  Q-  - C . . . . . . . . . . .  A . . . . . . . . . . . . . . . . . .  
301  360  
CTTGACTTCA TCTA~CAGCGG AACCAETCCCA GCCATCACCC C ~  GGCCGACGTC 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . .  A . . . .  G -  -AT  G . . . . . . . . . . . . . . . . . . . . . . . .  A . . . . . . . . . . . . . .  
361  420 
ACCGCCGAGC TG~TCG~I~z~ CCACGGTGTC ATGGCTTGCG GTACCGTCCA C ~ T C  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . . .  TG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ~ .  . . . . . . . . . . . . . .  
421"  480  
GAATaI J~AC TT  GACCCCCAAe AACC Ta%ACCA AACCAACTTG GATATTCATT GT .ACAAAGTT 
. . . . . . . . . . . . . .  T .~LCCT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . . . .  • -+- -A  . . . . . .  • , - -e , - ,  . . . . . . . . . . . . . .  T . . . . . .  
481  539  
G&TTT I~TCA ATCTCTTA,C  I~CA~Ta~TT GATTCGATAA C ~  
. . . . . . . . . . . . . . . . . .  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . .  G . . . . . .  T . . . .  TT  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Fig. 1. Comparison of nucleotide sequences of Lep d 1 cDNA clones Lep d 1.0101, Lep d 1.0102 and Lep d 1.02. The sequences begin with the first 
nucleotide ofATG start codon. Identities with Lep d 1.0101 sequence are indicated with dashes. Gaps are introduces for alignment purposes. Brackets 
represent the leader sequence and the asterisks indicate the stop codon. 
therefore could not distinguish different is•allergens and vari- 
ants. Their analysis indicated six polymorphic sites, whereas 
our cDNA data identified 13 such sites; these also include the 
six previously identified by those authors. Although it is plausi- 
ble that intermediate forms exist, they probably only exist in 
minute amounts. 
The comparison of the cDNA with other nucleotide se- 
quences using GCG BLASTN [17] showed a significant homol- 
ogy with group II allergens from Dermatophagoides. Lep d 1.01 
and Lep d 1.02 showed 52% identity with Der p 2 and 57% with 
Der f 2. In earlier studies, we have shown a limited amount of 
allergenic cross-reactivity between Lep d 1 and Dermatophagoi- 
Lep d 
Lep d 
Lep d 
Lep d 
Lep d 
Lep d 
kep d 
Lep d 
Lep d 
Lep d 
Fig. 2. Comparison of the amino 
1.01 1 M M K F  I A L F A L V A V A S A G K M T F K D  C G H G E V T E  L 32  
1.02  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
1.01 33 D I TGC S GD T C V I  H R G E K M T L E A K F A A N Q D T A K  64  
1.02  - - S . . . . . . . . . . . .  O . . . .  D . . . . . . . . .  N -  
1.01 65  VT  I K V L A K V A G T  T I  Q V P G L E  TD G C K F I  K C P V K  96  
1.02 . . . . . . . . . . . . . . . . . . . . . . . . .  VL  - - - I - 
101 97 K G E A L D F X Y  S G T I P A I  T P K V K A D V T A E L I G D H  128 
102  . . . . . . .  N - G M . . . . . . . .  I . . . . . . . .  V - - - 
1.01 129  G V M A C G T V H G O V E  141  
1.02 . . . . . . .  I . . . . .  
acid composition of Lep d 1.01 and Lep d 1.02. Only those of Lep d 1.02 that differ from Lep d 1.01 are given. 
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480 525 
Lop  d 1 .0101 ~Ut.~r'T. JULTC ~TCTCTT. iU3  ~ G,~L~'Z'CG~.JUk CT~'M~ 
c lone  L2 . . . . . . .  T -  • - -  o - -Ao  • . . . . . . . . . . . .  T . . . .  A -A  . . . . . . . .  
Fig. 3. Partial comparison of the 3' non-coding region of Lep d 1.0102 and clone L2 [11]. Identities are indicated by dashes, gaps are introduced 
for alignment purposes, and the polyA signal is underlined. 
des pteronyssinus [8]. In regard to the function of group 2 
allergens of Dermatophagoides, there is accumulating evidence 
that they are lysozymes [18]. The function of Lep d 1 is so far 
unclear. However, the localization of Lep d 1 in the digestive 
tract of the mite and the fecal pellets [19] indicates that the 
allergen is involved in digestion which makes it reasonable to 
assume that it is an enzyme. 
Lep d 1 is a major allergen of the storage mite Lepidoglyphus 
destructor, and most patients how lgE reactivity to it. This is 
the first report that substantiates the existence of polymorphic 
forms for Lep d 1 based on cDNA analysis. 
We have successfully cloned and sequenced two isoallergens 
and variants of that protein. A baculovirus expression system 
utilizing insect cells should allow us to express the proteins in 
their native conformation. Knowledge of the sequence and the 
ability to express the proteins and fragments that include T and 
B cell epitopes will allow us to study both the different and 
common effects of the two isoforms. In addition, the expressed 
proteins will be useful as diagnostic tools and could eventually 
lead to immunotherapy with a mixture of T cell epitope pep- 
tides, rather than with highly allergenic mite proteins. 
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